Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Schizophrenia

Free Subscription Articles published in PLoS One Retrieve available abstracts of 68 articles: HTML format

Single Articles

January 2025
1. LANGE M, Koliousis A, Fayez F, Gogarty E, et al
   Schizophrenia more employable than depression? Language-based artificial intelligence model ratings for employability of psychiatric diagnoses and somatic and healthy controls.
   PLoS One. 2025;20:e0315768.
   PubMed     Abstract available
   
   
   
2. KHAN M, Batool R, Mushtaq U, Iqbal S, et al
   MESS to live with schizophrenic parental history: A systematic review of developmental checkpoints.
   PLoS One. 2025;20:e0313531.
   PubMed     Abstract available
   
   
   
3. HAZAN H, Funaro MC, Srihari VH
   Measurement properties of instruments to assess insight in psychosis: A systematic review protocol.
   PLoS One. 2025;20:e0316447.
   PubMed     Abstract available
   
   
   
4. ZHAO R, Shi H, Wang Y, Jiang T, et al
   Allele-specific methylation of SSTR4 associated with aging and cognitive functions in patients with schizophrenia.
   PLoS One. 2025;20:e0303038.
   PubMed     Abstract available
   
   
   
5. HAZAN H, Tayfur SN, Zhou B, Li F, et al
   The impact of Duration of Untreated Psychosis on functioning and quality of life over one year of Coordinated Specialty Care (CSC).
   PLoS One. 2025;20:e0312740.
   PubMed     Abstract available
   
   
   
6. PARK SI, Kim S, Park K, Yu U, et al
   Predictors of clozapine concentration and psychiatric symptoms in patients with schizophrenia.
   PLoS One. 2025;20:e0319037.
   PubMed     Abstract available
   
   
   
7. LEE SC, Chiu EC
   Reliability of the Test of Visual Perceptual Skills-4th Edition for people with schizophrenia.
   PLoS One. 2025;20:e0318148.
   PubMed     Abstract available
   
   
   
8. MLAY JP, Naidu T, Ramlall S, Patankar K, et al
   Strategies for relapse prevention among people with schizophrenia in KwaZulu-Natal Province, South Africa: Healthcare providers' perspectives.
   PLoS One. 2025;20:e0316313.
   PubMed     Abstract available
   
   
   
9. JAMEIE M, Bordbar S, Samiee R, Amanollahi M, et al
   Monocytic TLR4 expression and activation in schizophrenia: A systematic review and meta-analysis.
   PLoS One. 2025;20:e0319171.
   PubMed     Abstract available
   
   
   
10. BEYENE MG, Teferra S, Fenta TG
    Non-adherence and predictors in patients with schizophrenia on second generation antipsychotics at Amanuel Mental Specialized Hospital, Ethiopia.
    PLoS One. 2025;20:e0314403.
    PubMed     Abstract available
    
    
    
11. RESHID Z, Haile K, Ayano G, Kebede A, et al
    Assessment of treatment outcomes and associated factors among patients treated with clozapine at amanuel mental specialized hospital, Addis Ababa, Ethiopia.
    PLoS One. 2025;20:e0321536.
    PubMed     Abstract available
    
    
    
12. TAO F, Deng S, Zhuo B, Liu J, et al
    Causal relationship between schizophrenia and five types of dementia: A bidirectional two-sample Mendelian randomization study.
    PLoS One. 2025;20:e0322752.
    PubMed     Abstract available
    
    
    
13. AHMADZADEH K, Sarabi-Jamab A, Beiranvand F, Forouzandeh M, et al
    Moral decision-making is altered in patients with schizophrenia.
    PLoS One. 2025;20:e0322614.
    PubMed     Abstract available
    
    
    
14. NGONGI LI, Akiba CF, Kilonzo MN, Minja AA, et al
    Barriers, facilitators and potential solutions to implementing Kiddie Schedule for Affective Disorder and Schizophrenia (KSADS) screening tool at Muhimbili National Hospital in Dar es Salaam, Tanzania.
    PLoS One. 2025;20:e0323502.
    PubMed     Abstract available
    
    
    
15. HONG Y, Chen Y, Bai Y, Tan W, et al
    Cognitive-behavioral therapy for the improvement of negative symptoms and functioning in schizophrenia: A systematic review and meta-analysis of randomized controlled trials.
    PLoS One. 2025;20:e0324685.
    PubMed     Abstract available
    
    
    
16. HOU PH, Chang GR, Chao YT, Chang YT, et al
    Aripiprazole use and lowering the risk of breast cancer in patient with schizophrenia in a national cohort study.
    PLoS One. 2025;20:e0324257.
    PubMed    
    
    
    
17. FEKIH-ROMDHANE F, Saguem BN, Stambouli M, Hallit S, et al
    Violence victimization and perpetration within the caregiver-patient relationship in schizophrenia: A cross-sectional study in Tunisia.
    PLoS One. 2025;20:e0323312.
    PubMed     Abstract available
    
    
    
18. GEENJAAR E, Kim D, Calhoun V
    Providing context: Extracting non-linear and dynamic temporal motifs from brain activity.
    PLoS One. 2025;20:e0324066.
    PubMed     Abstract available
    
    
    
19. AN Y, Fang G, Pi Z, Zhang Y, et al
    Cost-utility of aripiprazole once-monthly versus paliperidone palmitate once-monthly injectable for schizophrenia in China.
    PLoS One. 2025;20:e0317393.
    PubMed     Abstract available
    
    
    
20. PATON J, van Boxtel JJA
    Attentional biases, as measured by motion-induced blindness, are linked to schizophrenia traits.
    PLoS One. 2025;20:e0325609.
    PubMed     Abstract available
    
    
    
21. GRAMAGLIA C, Gambaro E, Bestagini L, Bassi E, et al
    Nurse-led psychoeducational interventions in patients suffering from schizophrenia or other psychotic disorders and their families: A scoping review protocol.
    PLoS One. 2025;20:e0327486.
    PubMed     Abstract available
    
    
    
22. ZEMMOUR K, Samson GO, Fortier M, Parent E, et al
    Brain glucose and ketone metabolism in first-episode psychosis: Neuroimaging and brain metabolism before and after antipsychotic treatment: The protocol for the CAST-ATP study.
    PLoS One. 2025;20:e0325489.
    PubMed     Abstract available
    
    
    
23. PIRANI A, Sarabi-Jamab A, Bostan F, Salehian R, et al
    Differential cognitive and clinical improvements in Schizophrenia and bipolar disorder following hospitalization: A comparative analysis based on the Clock Drawing Test.
    PLoS One. 2025;20:e0325537.
    PubMed     Abstract available
    
    
    
24. HERNADI Z, Kormoczi L, Adlan LG, Kekesi G, et al
    Categorized and individualized behavioral phenotyping approaches for control and triple-hit schizophrenia-like model rats in acute and chronic reward-based systems: A pilot study.
    PLoS One. 2025;20:e0328460.
    PubMed     Abstract available
    
    
    
25. GUO Y, Wu J, Lei X, Zhang H, et al
    The relationship between sarcopenic obesity and cognitive functionality among inpatients with stable schizophrenia.
    PLoS One. 2025;20:e0330453.
    PubMed     Abstract available
    
    
    
26. CAVANAH LR, Tian MY, Goldhirsh JL, Huey LY, et al
    Declines and pronounced state-level variation in clozapine use among Medicare patients.
    PLoS One. 2025;20:e0328495.
    PubMed     Abstract available
    
    
    
27. DONATH VM, Ries ES, Mariegaard L, Kristensen TD, et al
    Alleviating negative symptoms in schizophrenia using a virtual reality-based therapy targeting social reward learning (ENGAGE): Protocol for a randomised, controlled, assessor-blind pilot study.
    PLoS One. 2025;20:e0331632.
    PubMed     Abstract available
    
    
    January 2024
28. PEREZ-ROMERO N, Campos-Jara C, Pesce C, Araya Sierralta S, et al
    Effects of physical exercise on executive functions of individuals with schizophrenia spectrum disorders: Protocol for a systematic review and meta-analysis.
    PLoS One. 2024;19:e0296273.
    PubMed     Abstract available
    
    
    
29. CLEMMENSEN L, Lund CN, Andresen BS, Midtgaard J, et al
    Study protocol for RUFUS-A randomized mixed methods pilot clinical trial investigating the relevance and feasibility of rumination-focused cognitive behavioral therapy in the treatment of patients with emergent psychosis spectrum disorders.
    PLoS One. 2024;19:e0297118.
    PubMed     Abstract available
    
    
    
30. JAKA S, Singh S, Vashist S, Pokhrel S, et al
    Pediatric anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis: Exploring psychosis, related risk factors, and hospital outcomes in a nationwide inpatient sample: A cross-sectional study.
    PLoS One. 2024;19:e0296870.
    PubMed     Abstract available
    
    
    
31. ROSADO D, Intriago B, Loor E, Alcivar F, et al
    Associations between Toxoplasma gondii seropositivity and psychopathological manifestations in schizophrenic patients: A single-center study from Ecuador.
    PLoS One. 2024;19:e0297523.
    PubMed     Abstract available
    
    
    
32. FEIJS HME, van Aken L, van der Veld WM, van der Heijden PT, et al
    No relations between executive functions and dimensional models of psychopathology or is time the missing link?
    PLoS One. 2024;19:e0288386.
    PubMed     Abstract available
    
    
    
33. 
    Expression of Concern: Synaptic Dysbindin-1 Reductions in Schizophrenia Occur in an Isoform-Specific Manner Indicating Their Subsynaptic Location.
    PLoS One. 2024;19:e0301152.
    PubMed    
    
    
    
34. LIU J, Sun SJ, Lu Y, Ping X, et al
    Taste dysfunction as a predictor of depression in schizophrenia: A systematic review and meta-analysis.
    PLoS One. 2024;19:e0300935.
    PubMed     Abstract available
    
    
    
35. BASU A, Dutta AK, Bagepally BS, Das S, et al
    Pharmacogenomics-assisted schizophrenia management: A hybrid type 2 effectiveness-implementation study protocol to compare the clinical utility, cost-effectiveness, and barriers.
    PLoS One. 2024;19:e0300511.
    PubMed     Abstract available
    
    
    
36. MUSLIH M, Chung MH
    Structural validity of the Rosenberg self-esteem scale in patients with schizophrenia in Indonesia.
    PLoS One. 2024;19:e0300184.
    PubMed     Abstract available
    
    
    
37. HANLON C, Roberts T, Misganaw E, Malla A, et al
    Studying the context of psychoses to improve outcomes in Ethiopia (SCOPE): Protocol paper.
    PLoS One. 2024;19:e0293232.
    PubMed     Abstract available
    
    
    
38. 
    Correction: Integrated bioinformatics and statistical approach to identify the common molecular mechanisms of obesity that are linked to the development of two psychiatric disorders: Schizophrenia and major depressive disorder.
    PLoS One. 2024;19:e0304339.
    PubMed     Abstract available
    
    
    
39. HASSANZADEH R, Abrol A, Pearlson G, Turner JA, et al
    A confounder controlled machine learning approach: Group analysis and classification of schizophrenia and Alzheimer's disease using resting-state functional network connectivity.
    PLoS One. 2024;19:e0293053.
    PubMed     Abstract available
    
    
    
40. RAHMAN A, Russell M, Zheng W, Eckrich D, et al
    SARS-CoV-2 infection is associated with an increase in new diagnoses of schizophrenia spectrum and psychotic disorder: A study using the US national COVID cohort collaborative (N3C).
    PLoS One. 2024;19:e0295891.
    PubMed     Abstract available
    
    
    
41. EGGER JR, Kaaya S, Swai P, Lawala P, et al
    Functioning and quality of life among treatment-engaged adults with psychotic disorders in urban Tanzania: Baseline results from the KUPAA clinical trial.
    PLoS One. 2024;19:e0304367.
    PubMed     Abstract available
    
    
    
42. FASSLER L, Bighelli I, Leucht S, Sabe M, et al
    Targeted psychological and psychosocial interventions for auditory hallucinations in persons with psychotic disorders: Protocol for a systematic review and meta-analysis.
    PLoS One. 2024;19:e0306324.
    PubMed     Abstract available
    
    
    
43. WANG Y, Bi S, Li X, Zhong Y, et al
    Perturbations in gut microbiota composition in schizophrenia.
    PLoS One. 2024;19:e0306582.
    PubMed     Abstract available
    
    
    
44. KOLIND ME, Kruse R, Petersen AS, Larsen CS, et al
    Investigating the role of obesity, circadian disturbances and lifestyle factors in people with schizophrenia and bipolar disorder: Study protocol for the SOMBER trial.
    PLoS One. 2024;19:e0306408.
    PubMed     Abstract available
    
    
    
45. MATHIS WS, Ferrara M, Cahill J, Karmani S, et al
    TimelinePTC: Development of a unified interface for pathways to care collection, visualization, and collaboration in first episode psychosis.
    PLoS One. 2024;19:e0302116.
    PubMed     Abstract available
    
    
    
46. HUSAIN MO, Hawke LD, Lu Y, Kozloff N, et al
    A mixed-methods study to evaluate the feasibility and preliminary efficacy of delivering the optimal health program (OHP) for youth at clinical high risk (CHR) for psychosis: A study protocol.
    PLoS One. 2024;19:e0306968.
    PubMed     Abstract available
    
    
    
47. FITZGERALD I, Sahm LJ, Howe J, Maidment I, et al
    Shared decision-making interventions in the choice of antipsychotic prescription in people living with psychosis (SHAPE): Protocol for a realist review.
    PLoS One. 2024;19:e0304626.
    PubMed     Abstract available
    
    
    
48. REQUENA SS, Loch AA, Mendes KN, Reavley NJ, et al
    Development of mental health first aid guidelines for psychosis for Brazil: A Delphi expert consensus study.
    PLoS One. 2024;19:e0307064.
    PubMed     Abstract available
    
    
    
49. OSTERGAARD FG, Penninx BWJH, Das N, Arango C, et al
    The aperiodic exponent of neural activity varies with vigilance state in mice and men.
    PLoS One. 2024;19:e0301406.
    PubMed     Abstract available
    
    
    
50. MIEDLICH SU, Sahay P, Olivares TE, Lamberti JS, et al
    Lifestyle and mood correlates of cardiometabolic risk in people with serious mental illness on second-generation antipsychotic medications.
    PLoS One. 2024;19:e0306798.
    PubMed     Abstract available
    
    
    
51. MUSLIH M, Chung MH
    Correction: Structural validity of the Rosenberg self-esteem scale in patients with schizophrenia in Indonesia.
    PLoS One. 2024;19:e0308836.
    PubMed     Abstract available
    
    
    
52. HALLAJIAN AH, Sharifi K, Rostami R, Saeed F, et al
    Neurocognitive effects of 3 mA prefrontal electrical stimulation in schizophrenia: A randomized sham-controlled tDCS-fMRI study protocol.
    PLoS One. 2024;19:e0306422.
    PubMed     Abstract available
    
    
    
53. BOSWORTH ML, Isles AR, Wilkinson LS, Humby T, et al
    Sex-dependent effects of Setd1a haploinsufficiency on development and adult behaviour.
    PLoS One. 2024;19:e0298717.
    PubMed     Abstract available
    
    
    
54. LIM MJH, Iyyalol R, Lee JWY, Martin-Iverson MT, et al
    Multi-modal and bi-directional effects of a synthetic Delta9-Tetrahydrocannabinol (THC) analogue, Nabilone, on spatio-temporal binding windows: Evidence from the projected hand illusion.
    PLoS One. 2024;19:e0309614.
    PubMed     Abstract available
    
    
    
55. PU J, Wang B, Wang Y
    Validity of handgrip strength for assessing cognition and psychotic symptoms in hospitalized patients with stable schizophrenia.
    PLoS One. 2024;19:e0308133.
    PubMed     Abstract available
    
    
    
56. TYAS TH, Good MD, Pratikno B, Subandi MA, et al
    Unlocking the mentally ill in Indonesia: An empirical study of the effectiveness of a "Bebas Pasung" program in Central Java.
    PLoS One. 2024;19:e0302190.
    PubMed     Abstract available
    
    
    
57. WANG B, Zhou Y, Yu H, Jiang T, et al
    Correlations between nutritional indicators and cognitive function in patients with stable schizophrenia in a hospital setting.
    PLoS One. 2024;19:e0312227.
    PubMed     Abstract available
    
    
    
58. ROOSENSCHOON BJ, Deen ML, van Weeghel J, Kamperman AM, et al
    Illness (self) management, clinical and functional recovery as determinants of personal recovery in people with severe mental illnesses: A mediation analysis.
    PLoS One. 2024;19:e0313202.
    PubMed     Abstract available
    
    
    
59. SAMSON C, Livet A, Gilker A, Potvin S, et al
    Reasoning and interpretation cognitive biases related to psychotic characteristics: An umbrella-review.
    PLoS One. 2024;19:e0314965.
    PubMed     Abstract available
    
    
    
60. LEE CY, Ahmed N, Ikhtabi S, Duffett P, et al
    The experience of loneliness among people with psychosis: Qualitative meta-synthesis.
    PLoS One. 2024;19:e0315763.
    PubMed     Abstract available
    
    
    January 2023
61. CHAVES MF, Rodrigues C, Ribeiro S, Mota NB, et al
    Grammatical impairment in schizophrenia: An exploratory study of the pronominal and sentential domains.
    PLoS One. 2023;18:e0291446.
    PubMed     Abstract available
    
    
    
62. AGARWAL SM, Dissanayake J, Agid O, Bowie C, et al
    Characterization and prediction of individual functional outcome trajectories in schizophrenia spectrum disorders (PREDICTS study): Study protocol.
    PLoS One. 2023;18:e0288354.
    PubMed     Abstract available
    
    
    
63. MARTZOUKOU M, Papadopoulos D, Kosmidis MH
    Syntactic and affective prosody recognition: Schizophrenia vs. Autism spectrum disorders.
    PLoS One. 2023;18:e0292325.
    PubMed     Abstract available
    
    
    
64. JUCHNOWICZ D, Dzikowski M, Rog J, Waszkiewicz N, et al
    The usefulness of a complete blood count in the prediction of the first episode of schizophrenia diagnosis and its relationship with oxidative stress.
    PLoS One. 2023;18:e0292756.
    PubMed     Abstract available
    
    
    
65. LYLES S, Khan Z, Qureshi O, Shaikh M, et al
    A systematic review of the effectiveness and implementation readiness of psychosocial interventions for psychosis in South Asia.
    PLoS One. 2023;18:e0283411.
    PubMed     Abstract available
    
    
    
66. CLEMENTI L, Arnone E, Santambrogio MD, Franceschetti S, et al
    Anatomically compliant modes of variations: New tools for brain connectivity.
    PLoS One. 2023;18:e0292450.
    PubMed     Abstract available
    
    
    
67. ABDIN E, Seet V, Jeyagurunathan A, Tan SC, et al
    Validation of the 12-item World Health Organization Disability Assessment Schedule 2.0 in individuals with schizophrenia, depression, anxiety, and diabetes in Singapore.
    PLoS One. 2023;18:e0294908.
    PubMed     Abstract available
    
    
    
68. LAWRIE S, Hanlon C, Manda-Taylor L, Knapp M, et al
    Psychosis Recovery Orientation in Malawi by Improving Services and Engagement (PROMISE) protocol.
    PLoS One. 2023;18:e0293370.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Schizophrenia is free of charge.